A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.
A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.
复制标题
DOI：
10.1054/bjoc.2000.1295
复制
发表时间：
2000-08
影响因子：
8.8
通讯作者：
Bokemeyer C
中科院分区：
文献类型：
--
作者：
Kollmannsberger C;Quietzsch D;Haag C;Lingenfelser T;Schroeder M;Hartmann JT;Baronius W;Hempel V;Clemens M;Kanz L;Bokemeyer C
目的评价紫杉醇、顺铂联合持续滴注5-FU/亚叶酸治疗不能切除、局部进展期或转移性胃腺癌(PTS)的毒性和疗效。纳入45例化疗初治患者(男28例，女17例)，中位年龄60岁(范围35-74岁)。5-FU 2g/m2，每周1次，静脉滴注，疗程均为24小时。亚叶酸500 mg/m2，静脉滴注2小时。紫杉醇175 mg/m2于第1、22天静脉滴注3h，顺铂50 mg/m2于第8、29天静脉滴注1h。治疗6周(第1、8、15、22、29、36天)后休息2周为一个周期。45例患者接受了中位3个周期(范围1-4)的治疗，可评估其疗效、存活率和毒性。CR5例(11%)，PR 18例(40%)(ORR51%；95%CI：35.8~66.3%)。在肝、淋巴结、肺和原发肿瘤部位均有反应。9例(20%)病情稳定。13例(29%)被认为治疗失败，8例(18%)是由于进展性疾病，5例(11%)由于急性非血液毒性而没有接受一个完整的治疗周期。中位无进展生存时间为9个月(1~36+)，总生存期为14个月(2~36+)。发生中性粒细胞减少7例(15%)，仅1例出现IV级。其他非血液学毒性包括恶心/呕吐5例(11%)，脱发22例(49%)，腹泻各1例(2%)。有8例(17%)需要减少剂量或延迟治疗，主要原因是中性粒细胞减少。所有患者均在门诊基础上接受治疗。紫杉醇、顺铂联合持续输注5-FU/亚叶酸是治疗晚期胃癌的有效方案。虽然总体可接受的毒性允许它用于姑息治疗，但它也可能是一个有吸引力的选择，用于测试新辅助或辅助治疗。©2000癌症研究活动
To evaluate the toxicity and efficacy of combination chemotherapy with paclitaxel, cisplatin and 24 h continuous infusion of 5-FU/folinic acid in patients (pts) with unresectable, locally advanced or metastatic gastric adenocarcinoma. Forty-five chemotherapy-naive pts (28 male and 17 female) with a median age of 60 years (range 35–74) were enrolled. 5-FU 2 g/m2was given weekly over 24 h i.v. preceded by folinic acid 500 mg/m2as a 2 h infusion. Paclitaxel 175 mg/m2was administered as a 3 h-infusion on days 1 and 22 and cisplatin 50 mg/m2as 1 h infusion on days 8 and 29. Six weeks of therapy (days 1, 8, 15, 22, 29, 36) followed by 2 weeks rest were considered one cycle. A median of 3 cycles (range 1–4) were administered to 45 pts assessable for response, survival and toxicity. Five pts (11%) obtained a CR and 18 pts (40%) a PR (ORR 51%; 95% Cl: 35.8–66.3%). Responses were achieved in the liver, lymph nodes, lungs and at the site of the primary tumour. Nine pts (20%) had stable disease. Thirteen pts (29%) were considered to have failed treatment, 8 pts (18%) due to progressive disease and 5 pts (11%) who did not receive one complete cycle of therapy due to acute non-haematologic toxicity. The median progression-free and overall survival times were 9 months (range 1–36+) and 14 months (range 2–36+), respectively. Neutropenia WHO III°/IV° occurred in 7 pts (15%) with only 1 pt having grade IV. Additional non-haematologic WHO III°/IV° toxicities included nausea/vomiting in 5 (11%), alopecia in 22 (49%), and diarrhoea in 1 patient each (2%). Dose reductions or treatment delays were necessary in 8 pts (17%), mainly due to neutropenia. All pts were treated on an outpatient basis. The combination of paclitaxel, cisplatin and continuously infused 5-FU/folinic acid appears to be a highly active regimen for the treatment of pts with advanced gastric cancer. While the overall acceptable toxicity allows its use in the palliative setting, it may also be an attractive option to be tested for neoadjuvant or adjuvant treatment. © 2000 Cancer Research Campaign
登录
查看更多内容
DOI：
10.1073/pnas.83.23.8923
发表时间：
1986-12-01
影响因子：
11.1
作者：
SCANLON, KJ;NEWMAN, EM;PRIEST, DG
通讯作者：
PRIEST, DG
影响因子：
45.3
作者：
KELSEN, D;ATIQ, OT;BRENNAN, M
通讯作者：
BRENNAN, M
影响因子：
8.4
作者：
Cascinu, S;Ficarelli, R;Cellerino, R
通讯作者：
Cellerino, R
影响因子：
8.8
作者：
Pyrhonen, S;Kuitunen, T;Nyandoto, P;Kouri, M
通讯作者：
Kouri, M
影响因子：
2.3
作者：
Cascinu, S;Graziano, F;Catalano, G
通讯作者：
Catalano, G